Nanotechnology

[shaneyboy]

CLBE Enter Symbol(s): Go Find Symbol

Markets Stocks Funds Bonds ETFs
SessionsIR.com: GTx to continue with pivotal studies of Acapodene


By M2
Last Update: 1/23/2006 7:05:22 AM Data provided by

Jan 23, 2006 (M2 PRESSWIRE via COMTEX) -- Stocks in the News: EXACT Sciences Corp. (EXAS), Merck & Co. (MRK), GTx Inc. (GTXI)

For Corporate or Company information in regards to SessionsIR, please visit: www.sessionsir.com or contact us at: [e-mail].

For SherlockStock morning alerts, please visit: www.sherlockstock.com

CalbaTech, Inc. (CLBE) shares gained 5.77% on Friday, to finish up the week at $0.0275 per share, with above average volume trading. Calbatech is dedicated to offering products and platforms to the life sciences research market. Through its three divisions (Molecular Applications, Research Reagents, and Cellular Therapeutics) and several wholly owned subsidiaries (Molecula, KD Medical, LifeStem, and MolecularWare), the company is actively developing breakthrough innovations in biological discovery.

EXACT Sciences Corp. (EXAS) shares surged 22.40% at the end of last week to close at $3.06 per share, with high volume. The Company announced on Thursday that it would be hosting its Fourth Quarter Earnings call on Tuesday, January 24th, at 8:30 am Eastern Time. To listen to the call, please visit: http://biz.yahoo.com/cc/1/64371.html Leonel Garza was 71 when he died of a heart attack, 23 years after being diagnosed with heart disease and decades after a heart attack and a quadruple bypass. But his lawyers who are suing Merck & Co. (MRK) say it was the Vioxx that he took for arm pain for 17 days that killed him. Jury selection is scheduled to begin Tuesday in Rio Grande City, a town of about 12,000 people less than five miles from the Texas-Mexico border. To read more about the case, please visit: http://biz.yahoo.com/ap/060122/vioxx_rio_grande_valley.html?.v=2 GTx Inc. (GTXI) on Thursday said an independent safety review board recommended that it continue clinical development with its two pivotal Phase III trials of Acapodene. The company, which focuses on men's health, is evaluating the use of the drug in 80 mg doses to treat the effects of androgen deprivation therapy in men with advanced prostate cancer. It is evaluating its use in 20 mg doses for the prevention of prostate cancer in high-risk men.

Fridays Close: The stock market was hammered this week by two factors. First, there was disappointment over guidance given in key earnings reports. Second, there was concern over the situation with Iran and the implications for oil prices.Oil prices hit first. The S&P 500 index fell 5 points on Tuesday after the Monday holiday. The main cause was a jump in oil prices to over $67 a barrel after veiled threats from Iran that oil supplies would be disrupted if the international community attempted to interfere with its nuclear plans. Then the earnings problems began. After the close on Tuesday, Intel reported fourth quarter profits three cents below expectations. Revenue was also less than expected. Worse, the company said that first quarter revenue would be far less than current Wall Street estimates. That afternoon, Yahoo also said that fourth quarter profits and revenue were below expectations. Guidance for the first quarter was viewed as disappointing.

ABOUT SESSIONSIR:

SessionsIR (http://www.sessionsir.com/) is a full service corporate communications firm that provides an information bridge to the investment community. SessionsIR equipped to handle all aspects of the complex process of bringing the most concise and vital information about a company to audiences specifically targeted on the basis of their interest and qualifications. In short, SessionsIR makes sure that those interested parties get the data they want about the companies in which they are interested without extraneous information, and enhances the ability of companies to transmit their customized message in the most efficient and effective manner possible.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or a solicitation to buy or sell securities. SessionsIR has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by SessionsIR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this release have not given an opinion or approved the statements made in this release.

SessionsIR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. SessionsIR affiliates, officers, directors and employees may also have bought, or may buy the shares discussed in this opinion and may profit in the event of a rise in value. SessionsIR will not advise as to when it decides to sell and does not, and will not, offer any opinion as to when others should buy or sell; each investor must make that decision based on his or her judgment of the market. SessionsIR press releases are used only for informational purposes. Please consult your broker before purchasing or selling any securities mentioned herein.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].